AzTrials
AzTrials

UrticariaNCT03296358

Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.

A study testing IV Dexamethasone and Oral prednisolone in people with Urticaria and Allergy, run by Chulalongkorn University at 1 site in Thailand.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A randomized, double-blinded, controlled trial of adding a short burst of corticosteroid to the conventional treatment of H1 antihistamines Read more about this study

Who is it for?
Ages 18 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Urticaria, Allergy
What is being tested?
IV Dexamethasone and Oral prednisolone
Could I receive a placebo?
No, everyone receives an active treatment
How many people
75 participants
Where
1 siteThailand
Study dates
1 Oct 2017to 31 Oct 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Patients visit emergency room at King chulalongkorn memorial hospital (KCMH) age between 18-50 years who meet the following criteria of acute urticarial such as
  • eruption of wheals, central swelling of various sizes, with or without surrounding erythema; with or without angioedema
  • pruritus or occasional burning sensation
  • skin returning to normal appearance, usually within 1-24 hours

Who cannot join

  • patients who have urticarial for more than 48 hours
  • have severe underlying disease such as heart disease, kidney disease, liver disease
  • pregnancy
  • history of chlorpheniramine maleate, steroid, antihistamines allergy
  • history of antihistamine or steroid uses within 48 hours before ED visit
  • diabetes mellitus
Show all 9Show fewer
  • suspected of more severe disease or severe allergic reaction
  • patients who don't have pruritus
  • patients who have history of chronic urticaria

Trial locations and contacts

1 site in 1 country.

Thailand1 site
  • Chulalongkorn Hospital

    Pathum Wan, Bangkok, 10600

Other trials in Thailand

About this study

Official title: A Randomized, Double-blinded, Controlled Trial of Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines

A randomized, double-blinded, controlled trial of adding a short burst of corticosteroid to the conventional treatment of H1 antihistamines

Read the detailed description

Research Methodology

Target Population Patients visit emergency room at King chulalongkorn memorial hospital (KCMH) age between 18-50 years who meet the following criteria of acute urticarial such as

  1. eruption of wheals, central swelling of various sizes, with or without surrounding erythema; with or without angioedema
  2. pruritus or occasional burning sensation
  3. skin returning to normal appearance, usually within 1-24 hours

Exclusion criteria

  1. patients who have urticarial for more than 48 hours
  2. have severe underlying disease such as heart disease, kidney disease, liver disease
  3. pregnancy
  4. history of Chlorpheniramine, steroid, antihistamines allergy
  5. history of antihistamine or steroid uses within 48 hours before emergency department visit
  6. diabetes mellitus
  7. suspected of more severe disease or severe allergic reaction
  8. patients who don't have pruritus
  9. patients who have history of chronic urticaria

Informed consent process The doctor who is the principal investigator or his assigned colleagues describe the research's details and methods to an enrolled patients. The documents which contain the details of the research project are also given. Inform consents then were signed before the beginning of the experiment.

The volunteer would be in a research process during their first 1-2 hours in emergency department, with the follow up time at 1 week and 1 month

After the investigator complete the inclusion and exclusion criteria, the participants would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination :

  1. Control group : Chlorpheniramine 10 mg/amp ; 1 ampule and cetirizine 10 mg 7 tabs
  2. Experiment group : Chlorpheniramine 10 mg/amp ; 1 ampule, Dexamethasone 5 mg/amp; 1 ampule and cetirizine 10 mg 7 tabs
  3. Experiment group : Chlorpheniramine 10 mg/amp ; 1 ampule, Dexamethasone 5 mg/amp; 1 ampule, cetirizine 10 mg 7 tabs, and prednisolone 5 mg 20 tabs After the envelopes are sealed, it will be code in an order of number. All of the enrolled patients will get Chlorpheniramine 10 mg intravenous. The patients who are assigned in experiment group will get an additional Dexamethasone 5 mg intravenous. The preparation of both drugs will be result to be a 10 ml of clear fluid. The control group will get a 10 ml of sterile fluid in 10 ml syringe as a placebo. The drugs will be prepared and delivered be the nurse who knows about the research process but does not get involved in other process of the research.

After the experiment period in emergency department, all of the enrolled patients will get cetirizine 10 mg 7 tabs as a home medication. One experiment group will get prednisolone 5 mg 20 tabs. They will be appointed to an outpatient department in 1 week and 1 month for the follow up of an acute urticarial rash.

Sample size calculation Investigators do the hypothesis that the experiment groups who get both Chlorpheniramine 10 mg and Dexamethasone 5 mg intravenous would have the itch score decrease at least 2 points so this experiment wants minimal clinical difference at "2". This number got from our expert in immunology and skin disease. The standard deviation for this experiment is 2.1 from the previous research. Calculated by G*Power version 3.1 (Dusseldorf, Germany) for an independent t-test , two-tailed analysis, alpha error probability = 0.05 and power of analysis (1-beta error probability) = 0.90 The sample size for each group is 23 persons so the patients enroll in this research would be 69 persons.

Data Collection

  1. Sex and age
  2. Time since the first rash erupt before coming to emergency department (hrs)
  3. %body surface area of rash involved
  4. Urticarial activity score (UAS) before and after treatment
  5. Itch score (Visual analog scale (VAS) score) by letting the patients mark a cross on a straight line. The end of the left side of a line represents "0 = no pain at all", and the end of the right side of a line represents "10 = the worst pain ever possible". The patients aren't allowed to compare the previous VAS score before doing the cross.
  6. Side effect of drugs
  7. Other medicine used as indicated
  8. Patients' satisfaction score
  9. The recurrence of rash 1 week after the rash onset
  10. The recurrence of rash 1 month after the rash onset which will be evaluate by an expert in immunology and skin disease.

Data Analysis and Statistics

Descriptive statistics : Chi-square Student t-test and paired t-test for data analysis of continuous variables (such as itch score (VAS) and pair wise comparison for cumulative increase in the proportion of the "responder" over the time

Statistical significant when p-value < 0.05

Conditions
Urticaria, Allergy
Being tested
IV Dexamethasone, Oral prednisolone
Keywords
Acute urticaria, Emergency department, Acute allergic syndrome, Corticosteroid, H1-Antihistamines, Chronic urticaria
Medical subject headings
Urticaria, Hypersensitivity, Emergencies, Chronic Urticaria

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • IV DexamethasoneDrug

    Also called Decadron, Dexasone

    The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 1 and Experiment 2 groups would receive IV Dexamethasone in emergency department (ED).

  • Oral prednisoloneDrug

    Also called Orapred

    The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 2 groups would receive IV Dexamethasone in ED and Oral prednisolone as home medication.

Study groups in NCT03296358
Study groupRoleWhat they receive
Control groupNo interventionChlorpheniramine 10 mg/amp ; 1 ampule Cetirizine 10 mg 7 tabs once daily (OD) as home medication
Experiment 1ExperimentalChlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication
Receives: Drug: IV Dexamethasone
Experiment 2ExperimentalChlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication Oral prednisolone 5 mg 20 tabs ; 2*2 po pc as home medication
Receives: Drug: IV Dexamethasone; Drug: Oral prednisolone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Itch score

    letting the patients mark a cross on a straight line. The end of the left side of a line represents "0 = no itch at all", and the end of the right side of a line represents "10 = the worst itch ever possible". The patients aren't allowed to compare the previous VAS score before doing the cross.

    Measured: 60 mins

Secondary outcomes (2)
  1. Chronic urticaria incidence

    Chronic urticaria incidence after the use of steroid compare with no steroid use in treatment.

    Measured: 1 week, 1 month

  2. Itch score

    letting the patients mark a cross on a straight line. The end of the left side of a line represents "0 = no itch at all", and the end of the right side of a line represents "10 = the worst itch ever possible". The patients aren't allowed to compare the previous VAS score before doing the cross.

    Measured: 0, 15, 30 mins

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Sep 2017
  2. Study start1 Oct 2017
  3. Primary completion31 Oct 2019
  4. Study completion31 Oct 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
75 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03296358
Sponsor's protocol ID
668/2017
Status last verified
Jan 2020
First submitted
11 Sep 2017
Last updated
11 Feb 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing IV Dexamethasone and Oral prednisolone in people with Urticaria and Allergy, run by Chulalongkorn University at 1 site in Thailand.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Feb 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Itch score (time frame: 60 mins). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Feb 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in